Company: STAA
Filing Date: 2025-04-24
Form Type: DEF 14A
Source: 0000950170-25-058174
Chunk: 1

Company: STAAR SURGICAL CO
Filing Date: 2025-04-24
Form: DEF 14A
Chunk 1
---
 Evolution in Visual Freedom designed to provide premium refractive outcomes while optimizing patient comfort. STAAR Surgical is Ushering in the Next Generation of Vision Correction with EVO ICLTM Key Focus: Surgeon Education and Training STAAR University EVO Experience Center Ophthalmic conventions Research studies Papers and publications In March 2024, we celebrated a major milestone for STAAR - over 3 million of our Implantable Collamer® Lenses sold worldwide In April 2024, we launched STAAR University, which offers surgeons access to data, publications, and resources to support clinical confidence In September 2024, we opened a new EVO Experience Center at our headquarters in California to serve as a hub for hands-on training and education Strategic Imperatives for 2025 Support business in China by simplifying our revenue model and optimizing channel inventory as we work to streamline operations and position the Company for growth Accelerate Switzerland ICL production to supplement U.S. manufacturing capacity, mitigate potential tariff impacts, and bring manufacturing closer to customers Drive execution in key markets globally and increase adoption of lower diopter ICLs Expand product offering and regulatory approvals globally Increase awareness in patients and the medical community of the clinical benefits of our ICLs Rationalize cost structure to improve profitability and cash flow generation Continue to invest in product innovation and opportunities to expand the use of our proprietary biocompatible Collamer® material STAAR has outstanding products, a strong network of surgeons, and a clear path to continued market share gains in a market that we expect to grow substantially over time.

Dear Fellow Shareholders: Thank you for your continued support of STAAR Surgical Company. In 2024, STAAR continued to drive awareness of our advanced lens-based vision correction technology and invest in our company to build a foundation for future growth. Our Implantable Collamer ® Lenses (ICLs) have a history of proven success, and in March 2024, we celebrated a major milestone for our company - over 3 million ICLs sold worldwide. Our dedicated employees participated in major ophthalmic conventions around the world in 2024 to educate surgeons about the features and benefits of our ICLs, and we are investing in market development, practice support, healthcare professional training, and patient outreach to drive growth. We believe that patient awareness combined with surgeon education and training are critical to the continued adoption of the ICL procedure. In April 2024, we announced the launch of STAAR University, which offers surgeons access to publications, key clinical outcomes data, and